BrioLyfe
Cagrilintide | 5mg
Cagrilintide | 5mg
Couldn't load pickup availability
Cagrilintide is a long-acting amylin analog currently under investigation as a treatment for obesity and type 2 diabetes.
Mechanism of Action
Amylin is a hormone produced by the pancreas that helps regulate appetite and blood sugar levels. Cagrilintide is a synthetic version of amylin that is designed to have a longer half-life and be injected less frequently than natural amylin.
Cagrilintide works by:
Suppressing appetite, Slowing gastric emptying, and Reducing calorie intake.
Clinical Trials
Several clinical trials have evaluated the efficacy and safety of cagrilintide. In one trial, participants with obesity who received cagrilintide lost an average of 10% of their body weight over 26 weeks, compared to 3% in the placebo group. Another trial showed that cagrilintide improved blood sugar control and reduced weight in people with type 2 diabetes.
Combination Therapy
Cagrilintide is also being studied in combination with other medications for obesity and diabetes. For example, a study combining cagrilintide with semaglutide, another anti-obesity medication, showed greater weight loss than either medication alone.
Side Effects
The most common side effects of cagrilintide include nausea, vomiting, and diarrhea. These side effects are generally mild and tend to improve over time.
Future Directions
Cagrilintide is a promising new treatment option for obesity and diabetes. Further research is needed to determine the optimal dosage and combination therapies for cagrilintide. It is also important to evaluate its long-term safety and effectiveness.
5 mg – Batch CG25-05-001
99.8% purity | 5.67 mg
CAS NO: 1415456-99-3
Molecular Formula: C194H312N54O59S2
Molecular Weight: 4,409 g/mol
Appearance: white powder
Storage: 2-8°
Purity: ≥99
Please note that all products featured here are intended exclusively for research and development purposes. They are not designed for any form of human consumption. These products have not undergone evaluation by the U.S. Food and Drug Administration.
Share
